Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Jayne

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Annals of the Rheumatic Diseases|December 1, 2016
Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitisEmma E van Daalen, Raffaella Rizzo, Andreas Kronbichler, et al.
Lupus|March 19, 2025
Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trialRichard Furie, Jürgen Steffgen, Nora Fagan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 18, 2025
Risk factors for relapse in ANCA-associated vasculitis among patients with relapse after induction of remission with rituximabEllen Romich, Joshua F Baker, Thomas R Riley, et al.
Journal of the American Society of Nephrology : JASN|November 19, 2011
Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapyAnnelies E Berden, Rachel B Jones, Dianhdra D Erasmus, et al.
Rheumatology (Oxford, England)|October 5, 2017
Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up dataAnoek A E de Joode, Jan Stephan F Sanders, Xavier Puéchal, et al.
Rheumatology (Oxford, England)|March 4, 2025
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trialDuvuru Geetha, Christian Pagnoux, Sebastian E Sattui, et al.
BMJ Open|July 17, 2024
Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVasDominic Paul McGovern, Mark E McClure, Matthew Coates, et al.
Nature Reviews. Disease Primers|August 29, 2020
ANCA-associated vasculitisA Richard Kitching, Hans-Joachim Anders, Neil Basu, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2010
Histopathologic classification of ANCA-associated glomerulonephritisAnnelies E Berden, Franco Ferrario, E Christiaan Hagen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2019
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 PatientsMatthias A Cassia, Federico Alberici, Rachel B Jones, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Annals of the Rheumatic Diseases|December 1, 2016
Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitisEmma E van Daalen, Raffaella Rizzo, Andreas Kronbichler, et al.
Lupus|March 19, 2025
Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trialRichard Furie, Jürgen Steffgen, Nora Fagan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 18, 2025
Risk factors for relapse in ANCA-associated vasculitis among patients with relapse after induction of remission with rituximabEllen Romich, Joshua F Baker, Thomas R Riley, et al.
Journal of the American Society of Nephrology : JASN|November 19, 2011
Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapyAnnelies E Berden, Rachel B Jones, Dianhdra D Erasmus, et al.
Rheumatology (Oxford, England)|October 5, 2017
Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up dataAnoek A E de Joode, Jan Stephan F Sanders, Xavier Puéchal, et al.
Rheumatology (Oxford, England)|March 4, 2025
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trialDuvuru Geetha, Christian Pagnoux, Sebastian E Sattui, et al.
BMJ Open|July 17, 2024
Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVasDominic Paul McGovern, Mark E McClure, Matthew Coates, et al.
Nature Reviews. Disease Primers|August 29, 2020
ANCA-associated vasculitisA Richard Kitching, Hans-Joachim Anders, Neil Basu, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2010
Histopathologic classification of ANCA-associated glomerulonephritisAnnelies E Berden, Franco Ferrario, E Christiaan Hagen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2019
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 PatientsMatthias A Cassia, Federico Alberici, Rachel B Jones, et al.
Pageof 3